Turn Therapeutics (TTRX) Interest & Investment Income (2024 - 2026)
Turn Therapeutics (TTRX) posted quarterly Interest & Investment Income of $49679.0 for Q1 2026, up 861.84% year-over-year from $5165.0 in Q1 2025, and up 250.47% quarter-over-quarter from $14175.0 in Q4 2025.
Powered by 
Analysis
Turn Therapeutics (TTRX) Interest & Investment Income (2024 - 2026) Analysis & Trends
Turn Therapeutics' Interest & Investment Income history runs 3 years deep, the most recent figure standing at $49679.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 861.84% year-over-year to $49679.0; the TTM figure through Mar 2026 stood at $74130.0 (changed N/A YoY), while the FY2025 annual figure was $29583.0, up 3.04% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $49679.0, up from $14175.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $49679.0 in Q1 2026, with the low at $5111.0 in Q3 2025.
- The 3-year median for Interest & Investment Income is $6188.5 (2024), against an average of $14417.8.
- The sharpest annual moves came in 2025 and 2026: Interest & Investment Income slipped 21.97% in 2025, then soared 861.84% in 2026.
- Turn Therapeutics' Interest & Investment Income stood at $5827.0 in 2024, then soared by 143.26% to $14175.0 in 2025, then soared by 250.47% to $49679.0 in 2026.
- Business Quant data shows TTRX's Interest & Investment Income at $49679.0 in Q1 2026, $14175.0 in Q4 2025, and $5111.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Turn Therapeutics | 302.05 Mn | 302.05 Mn | - | -241,359.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -241,359.00 |
| Mar 31, 2026 | 49,679.00 |
| Dec 31, 2025 | 14,175.00 |
| Sep 30, 2025 | 5,111.00 |
| Jun 30, 2025 | 5,134.00 |
| Mar 31, 2025 | 5,165.00 |
| Dec 31, 2024 | 5,827.00 |
| Sep 30, 2024 | 6,550.00 |